Polylactide microparticles prepared by double emulsion/evaporation technique. I. Effect of primary emulsion stability.
The process of microencapsulation of proteins by double emulsion/evaporation in a matrix of polylactide (PLA) can be divided into three successive steps: first, an aqueous solution of the active compound is emulsified into an organic solution of the hydrophobic coating polymer; second, this primary water-in-oil emulsion (w/o) is dispersed in water with formation of a double water-oil-water emulsion (w/o/w); third, the organic solvent is removed with formation of solid microparticles. This paper focuses on the effect of primary emulsion stability on the morphology and properties of polylactide microparticles loaded with bovine serum albumin (BSA) used as model drug. Depending on the stability of the primary emulsion, the internal structure of microparticles can be changed from a multivesicular to a matrix-like structure. Similarly, the average porosity can be controlled in a range from a few tenths of a micron to ca. 20 to 30 microns. This morphology control could find potential applications not only for the controlled drug delivery but also for the production of microporous particles intended for some specific applications, such as cell culture supports and chromatographic matrices. Although, the interplay of several processing parameters (polymer precipitation rate, polymer coprecipitation with interfacial compounds such as protein or surfactant, stirring rate...) may not be disregarded, this study also indicated that a high loading of a hydrophilic drug can only be expected from a stable primary emulsion. When the stability of the primary emulsion is such as to prevent formation of macropores (> 10 microns), the total pore volume is close to that of the originally dispersed aqueous drug solution.
Center for Education and Research on Macromolecules (CERM), University of Liège, Belgium.
N
N
Nihant
C
C
Schugens
C
C
Grandfils
R
R
Jérôme
P
P
Teyssié
D003692:Delayed-Action Preparations; D004339:Drug Compounding; D004355:Drug Stability; D004655:Emulsions; D008855:Microscopy, Electron, Scanning; D010316:Particle Size; D011091:Polyesters / Q000737:chemistry*; D016062:Porosity; D012710:Serum Albumin, Bovine; D013499:Surface Properties; D013501:Surface-Active Agents / Q000737:chemistry
D003692:Delayed-Action Preparations; D004655:Emulsions; D011091:Polyesters; D013501:Surface-Active Agents; D012710:Serum Albumin, Bovine; C033616:poly(lactide)